A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies
Phase of Trial: Phase II
Latest Information Update: 27 May 2019
At a glance
- Drugs Imetelstat (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors Geron Corporation; Janssen Research & Development
- 19 Jul 2018 Status changed from active, no longer recruiting to completed.
- 16 Jun 2017 Planned primary completion date changed from 1 May 2017 to 16 Jan 2019.
- 02 Dec 2016 Planned End Date changed from 1 May 2018 to 1 Jan 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History